- Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
- New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
- Roche Annual General Meeting 2023
- Assemblée générale 2023 de Roche
- Roche Generalversammlung 2023
- FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
- Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Transaktion in Roche Inhaberaktien
- New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.01 |
---|---|
High | 32.85 |
Low | 31.90 |
Bid | 31.89 |
Offer | 33.13 |
Previous close | 32.46 |
Average volume | 218.91 |
---|---|
Shares outstanding | 6.47bn |
Free float | 291.27m |
P/E (TTM) | 16.88 |
Market cap | 231.94bn USD |
EPS (TTM) | 2.09 USD |
Annual div (ADY) | 1.21 EUR |
---|---|
Annual div yield (ADY) | 3.78% |
Div ex-date | Mar 16 2023 |
Div pay-date | Mar 27 2023 |
Data delayed at least 15 minutes, as of Mar 23 2023.
More ▼